The Minimal Residual Disease Testing Market size was valued at USD 1.92 billion in 2022 and is projected to grow from USD 2.17 billion in 2023 to USD 6.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.36% during the forecast period (2023 - 2032).
The factors that are influencing the growth of the market are the increasing incidence of hematological malignancies and rising cancer awareness initiatives by global health organizations.
FIGURE 1: MINIMAL RESIDUAL DISEASE TESTING MARKET, 2022 to 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The incidence of hematological malignancies, which are cancers of the blood and bone marrow, has been increasing globally over the past few decades. This increase is thought to be due to a combination of factors, including an aging population, a change in lifestyle, and a rising number of people with weakened immune systems. Moreover, according to GLOBOCAN 2020, new cases for leukemia were 474,519, non-Hodgkin lymphoma cases were 544,352, and Hodgkin cases were 83,087. Furthermore, initiatives are having a positive impact on cancer awareness and prevention. Global health organizations such as the World Health Organization (WHO), the Union for International Cancer Control (UICC), the World Cancer Research Fund International, and Worldwide Cancer Research are committed to continuing to raise cancer awareness and reduce the burden of cancer worldwide. Moreover, initiatives undertaken include providing information and education about cancer, supporting cancer research, advocating for cancer control policies, and empowering cancer survivors.
Therefore, rising incidences of minimal residual disease testing and growing awareness through global organization are fueling the growth of the market.
The Minimal Residual Disease Testing Market is segmented, based on technology, into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. The flow cytometry segment held the majority share of the market and next-generation sequencing (NGS) is the fastest-growing segment during the forecast year. The widely preferred technique for minimal residual disease testing is flow cytometry and NGS. The flow cytometry approach can find one cancer cell among 100,000 bone marrow cells and provide results that can be available in less than one day. Moreover, PCR tests provide advantages such as high sensitivity, specificity, reproducibility, and rapid turnaround time.
Thus, the above-mentioned technologies are widely preferred for hematological malignancies and provide immense advantages for diagnosing cancer, fostering the growth of the technology segment.
The Minimal Residual Disease Testing Market segmentation, based on application, includes lymphoma, leukemia, solid tumors, and others. The leukemia segment dominated the market in the base year, i.e., 2022, and lymphoma is the fastest-growing segment during the forecast period, 2023–2032. This is due to the rising incidence of both leukemia and lymphoma cases across the globe. Moreover, the rapid launch of minimal residual tests for leukemia is also boosting the growth of the segment. For instance, in October 2021, Sysmex Inostics, Inc. (US) launched a clinically validated liquid biopsy test for the detection of minimal residual disease (MRD) for acute myeloid leukemia (AML). This test is based on next-generation sequencing.
Therefore, the increasing incidences of hematological malignancies and the launch of innovative MRD testing that targets the NGS panel are positively impacting the growth of the market.
FIGURE 2: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Based on end user, the Minimal Residual Disease Testing Market has been segmented into hospitals & clinics, diagnostic laboratories, and others. The hospital & clinics segment dominated the market in 2022, and the diagnostic laboratories segment is the fastest-growing segment during the forecast period, 2023–2032. This is due to the rapid adoption of newly launched MRD tests at diagnostic centers as well as the frequent adoption of MSD tests by patients. Moreover, MRD tests are being popularized due to their immense benefits in diagnosing cancer. Furthermore, as per the research, MRD is being utilized by hospitals and clinics to monitor the effectiveness of cancer treatment and detect cancer recurrence early.
By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. In North America, the minimal residual disease testing market held the largest market share in 2022 due to the presence of major players in the US such as Adaptive Biotechnologies (US), Sysmex Inostics, Inc. (US), Arup Laboratories Inc. (US), ArcherDX, Inc. (US), and Asuragen Inc. (US). Additionally, the rising incidences of lymphoma and leukemia are driving the growth of the North America region. As per the American Cancer Society's estimated that there were 59,610 new cases of leukemia and 23,710 deaths from leukemia in the US in 2023. Further, 20,380 cases of acute myeloid leukemia were reported in 2023.
Hence, the presence of major players in the region and increasing incidences of cancer are fostering the growth of the North American minimal residual disease testing market.
Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
FIGURE 3: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The European minimal residual disease testing market accounted for the second-largest market share due to the growing geriatric population. The incidences of blood related cancers increase with increases in age. The risk of leukemia is more than 10 times higher in people over the age of 65 than in people under the age of 45. In September 2022, it has been estimated by the World Economic Forum that more than 30% of the European population are expected to be 65 or older by 2100. Thus, growing geriatric population will create greater opportunities for the Europe market during the forecast period. Moreover, the Germany minimal residual disease testing market held the largest market in 2022, and the France minimal residual disease testing market is projected to be the fastest-growing market in the Europe region.
The Asia-Pacific minimal residual disease testing market is the fastest growing region from 2023 to 2032, owing to the growing incidence of hematological cancer, increased geriatric population, and the strategic formation to meet the demand of customers boosts Asia-Pacific region growth. For instance, October 2021, Genetron Health (China) and Jiangsu Fosun (China) started commercialization of MRD detection test in China, also promoted Seq-MRD in hematologic-focused hospitals and clinics in China. This test provides accuracy, high throughput, cost-efficiency, uniformity and fast turnaround time. Furthermore, the China minimal residual disease testing market accounted for the largest market share in 2022, and the India minimal residual disease testing market is projected to be the fastest-growing market in the Asia-Pacific region.
The key players in the Minimal Residual Disease Testing Market are investing heavily in research and development in order to develop new and more sensitive MRD testing technologies. They are also expanding their geographic reach through product launches, contractual agreements, mergers & acquisitions, investments, and collaboration with other market players in order to make MRD testing more accessible to patients around the world.
Adaptive Biotechnologies (US) is a clinical-stage company that develops next-generation immunosequencing (NGS) platforms and products to help physicians diagnose, treat, and monitor patients with cancer and other diseases. The company has a wide range of locations in North America and Europe. Furthermore, in October 2022, Adaptive Biotechnologies (US) partnered with Epic Systems Corporation in order to integrate the clonoSEQ assay into Epic’s comprehensive electronic medical record (EMR) system. The clonoSEQ Assay has been monitored by the US Food and Drug Administration and approved for chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (ALL) to detect minimal residual disease.
Key Companies in the Minimal Residual Disease Testing Market are included.
Minimal Residual Disease Testing Market Industry Developments
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.92 billion |
| Market Size 2023 | USD 2.17 billion |
| Market Size 2032 | USD 6.38 billion |
| Compound Annual Growth Rate (CAGR) | 11.36% (2023-2032) |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2019 to 2021 |
| Forecast Units | Value (USD billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Technology, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Adaptive Biotechnologies (US), Sysmex Inostics, Inc. (US), Arup Laboratories Inc. (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Bio-Rad Laboratories, Inc. (US), Guardant Health (US), QIAGEN N.V. (Germany), FOUNDATION MEDICINE, INC. (US), GRAIL, Inc. (US), and others |
| Key Market Opportunities | ·      Technological advancements in minimal residual disease tests |
| Key Market Drivers | ·      Increasing incidence of hematological malignancies ·      Rising cancer awareness initiatives by global health organizations |
Minimal Residual Disease Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The Minimal Residual Disease Testing Market is anticipated to reach 6.38 billion at a CAGR of 11.36% during the forecast period of 2023-2032.
The US held the largest market with a 80-90% share of the North America market for minimal residual disease testing market in 2022.
The Minimal Residual Disease Testing Market is expected to grow at 11.36% CAGR during the forecast period from 2023 to 2032.
The North America region market held the largest market share in 2022 in the Minimal Residual Disease Testing Market.
The key players include Adaptive Biotechnologies (US), Sysmex Inostics, Inc. (US), Arup Laboratories Inc. (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Bio-Rad Laboratories, Inc. (US), Guardant Health (US), QIAGEN N.V. (Germany), FOUNDATION MEDICINE, INC. (US), GRAIL, Inc. (US), and others.
The flow cytometry technology segment led the Minimal Residual Disease Testing Market in 2022 with a market share of approximately 20-25%.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
